Targeting a specific enzyme to help cancer patients with severe weight loss
Targeting Transglutaminase 2 in cancer cachexia
This study is looking at how a protein called Transglutaminase 2 affects muscle loss in cancer patients, especially those with pancreatic cancer, and is testing if blocking a certain factor can help improve muscle health and survival, with the hope of finding better treatments for those dealing with this tough condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-10867437 on NIH RePORTER |
What this research studies
This research investigates the role of Transglutaminase 2 in cancer cachexia, a condition that severely affects the quality of life and survival of cancer patients, particularly those with pancreatic cancer. The study aims to understand the mechanisms behind muscle wasting and explore potential treatments that could reverse this debilitating condition. By using genetic mouse models, researchers are examining how inhibiting the expression of a specific transcription factor, Twist1, can improve muscle health and overall survival in cancer patients. The findings could lead to new therapeutic strategies for managing cachexia in individuals suffering from advanced cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients, especially those with pancreatic cancer, who are experiencing significant weight loss and muscle wasting.
Not a fit: Patients who are not diagnosed with cancer or those who do not exhibit symptoms of cachexia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options to improve muscle mass and quality of life for cancer patients experiencing cachexia.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways for treating cachexia, indicating that this approach may lead to significant advancements in patient care.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Atfi, Azeddine — Virginia Commonwealth University
- Study coordinator: Atfi, Azeddine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.